Rita Nanda

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.6Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Papers

Driven by 52 papers — median percentile 73. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06943-x

Top 27%

0.737DataRank

Top 27%18 citations

Jori Sheade, Fangyuan Zhao, Frederick M. Howard, Nora Jaskowiak, Jennifer F. Tseng +6 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Racial disparities in survival outcomes among breast cancer patients by molecular subtypes

Breast Cancer Research and Treatment(2021)10.1007/s10549-020-05984-w

N/A

0.581DataRank · unranked

47 citations

Brenda Copley, Qun Niu, Fang Liu, Julie A. Johnson, Thomas Sutton +11 more

Validation of the RSClin risk calculator in the National Cancer Data Base

Cancer(2023)10.1002/cncr.35163

Top 40%

0.479DataRank

Top 40%8 citations

Asim Dhungana, Fangyuan Zhao, Nan Chen, Sarah P. Shubeck, Olwen Hahn +8 more

The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer

HAL (Le Centre pour la Communication Scientifique Directe)(2023)10.21203/rs.3.rs-2667554/v1

N/A

0.396DataRank · unranked

13 citations

Jori Sheade, Fangyuan Zhao, Frederick M. Howard, Nora Jaskowiak, Jennifer F. Tseng +6 more

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1095

N/A

0.104DataRank · unranked

1 citations

Elena Michaels, Poornima Saha, Murtuza Rampurwala, Olwen Hahn, Frederick M. Howard +5 more

Validation of the RSClin risk calculator using the National Cancer Database (NCDB).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.549

N/A

0DataRank · unranked

0 citations

Alexander T. Pearson, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo, Frederick M. Howard

Clinical trials of immunotherapy in triple-negative breast cancer

Breast Cancer Research and Treatment(2022)10.1007/s10549-022-06665-6

N/A

0DataRank · unranked

55 citations

Alexander T. Pearson, Rita Nanda, Frederick M. Howard

Patient out-of-pocket savings with lower-dose trastuzumab.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e18828

N/A

0DataRank · unranked

1 citations

Alec Kacew, Po-Hung Hsieh, Anthony V. Serritella, Randall W. Knoebel, Rita Nanda +3 more

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy

Cancers(2022)10.3390/cancers14184436

N/A

0DataRank · unranked

23 citations

Nu N. Le, Natsuko Onishi, David C. Newitt, Lisa J. Wilmes, Jessica Gibbs +15 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy

Academic Radiology(2022)10.1016/j.acra.2022.02.008

N/A

0DataRank · unranked

9 citations

Federico Pineda, Frederick M. Howard, Elle Hill, Teodora Szasz, Rabia Safi +6 more

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.07.07.499039

N/A

0DataRank · unranked

7 citations

James M. Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn +8 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis

Research Square(2022)10.21203/rs.3.rs-1221704/v1

N/A

0DataRank · unranked

2 citations

Susana García‐Recio, Toshinori Hinoue4, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro +49 more

Racial/ethnic differences in telemedicine utilization and satisfaction among patients with breast cancer during the COVID-19 pandemic.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.28_suppl.384

N/A

0DataRank · unranked

0 citations

Fangyuan Zhao, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo, Jincong Q. Freeman

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence

npj Breast Cancer(2023)10.1038/s41523-023-00530-5

N/A

0DataRank · unranked

62 citations

James M. Dolezal, Sara Kochanny, Galina Khramtsova, Jasmine Vickery, Andrew Srisuwananukorn +8 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer

Magnetic Resonance Imaging(2023)10.1016/j.mri.2023.08.003

N/A

0DataRank · unranked

8 citations

Federico Pineda, Frederick M. Howard, Xiaobing Fan, Rita Nanda, Hiroyuki Abé +3 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13103

N/A

0DataRank · unranked

3 citations

Poornima Saha, Murtuza Rampurwala, Sailaja Kamaraju, Olwen Hahn, Frederick M. Howard +8 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

The impact of site-specific digital histology signatures on deep learning model accuracy and bias

Nature Communications(2021)10.1038/s41467-021-24698-1

N/A

0DataRank · unranked

293 citations

James M. Dolezal, Sara Kochanny, Jefree J. Schulte, Heather Chen, Lara R. Heij +8 more

The molecular portraits of breast tumors are conserved across microarray platforms

UNC Libraries(2020)10.17615/bz2a-5v55

N/A

0DataRank · unranked

191 citations

Matthew G. Ewend, Michael Mullins, Chad Livasy, Heidi J. Hansen, Mary C. Mone +26 more

Streamlining regulatory review in a multicenter platform trial: Opportunity to enhance patient centered care and drive innovation and efficiency.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1572

N/A

0DataRank · unranked

1 citations

Teresa Helsten, Brian Moore, Linda Neuhauser, Barbara LeStage, Paolo Castillo +12 more

Treatment and treatment-related toxicity following subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10051

N/A

0DataRank · unranked

1 citations

Yutaka Yasui, Emily Stene, Sarah Monick, Ryan K. Rader, Jori Sheade +12 more

Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.574

N/A

0DataRank · unranked

0 citations

Asim Dhungana, Fangyuan Zhao, Nan Chen, Sarah P. Shubeck, Olwen Hahn +8 more

Comparisons of telemedicine and in-person visits: Utilization, oncology services and satisfaction among patients with breast cancer.

JCO Oncology Practice(2023)10.1200/op.2023.19.11_suppl.517

N/A

0DataRank · unranked

0 citations

Fangyuan Zhao, Frederick M. Howard, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo +1 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0DataRank · unranked

447 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

UNC Libraries(2020)10.17615/bgrr-9v25

N/A

0DataRank · unranked

0 citations

Anna Maria Storniolo, Vered Stearns, Vandana G. Abramson, Joel S. Parker, Catherine Van Poznak +19 more

Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer

Science Advances(2024)10.1126/sciadv.adp2622

N/A

0DataRank · unranked

10 citations

Olivia C. Laxton, Gang Li, Jing Lin, Olga Karginova, Rita Nanda +4 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07515-3

N/A

0DataRank · unranked

8 citations

Christine Y. Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai, Katie Hall +8 more

Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study

JMIR Cancer(2024)10.2196/55438

N/A

0DataRank · unranked

5 citations

Fangyuan Zhao, Frederick M. Howard, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo +1 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

UNC Libraries(2024)10.17615/m9ck-zv98

N/A

0DataRank · unranked

0 citations

Jonathan C. Silverstein, AURORA US Network, Melina E Sanders, P.W. Laird, C.M. Perou +53 more

Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer

Journal of Oncology Pharmacy Practice(2024)10.1177/10781552241289581

N/A

0DataRank · unranked

0 citations

Elena Michaels, Eric C. Polley, Peter H. O’Donnell, Frederick M. Howard, Olwen Hahn +5 more

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.08.002

N/A

0DataRank · unranked

5 citations

Jincong Q. Freeman, Sri G. Yarlagadda, Aishwarya Atmakuri, Kevin Kalinsky, Lajos Pusztai +5 more

A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07626-5

N/A

0DataRank · unranked

2 citations

Margarite D. Matossian, Poornima Saha, Murtuza Rampurwala, Sailaja Kamaraju, Olwen Hahn +8 more

Discordance of Radiologic and Pathologic Complete Response in Patients with Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy

Academic Radiology(2025)10.1016/j.acra.2025.12.004

N/A

0DataRank · unranked

1 citations

Wenji Guo, Dezheng Huo, Rita Nanda, Kirti Kulkarni, Frederick M. Howard +1 more

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer

Research Square(2025)10.21203/rs.3.rs-6926989/v1

N/A

0DataRank · unranked

2 citations

Xiaopeng Sun, Ann Hanna, Andres A. Ocampo, Brandie C. Taylor, James R. Marshall +14 more

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

medRxiv(2025)10.1101/2025.08.25.25334393

N/A

0DataRank · unranked

0 citations

James M. Dolezal, Hanna M. Hieromnimon, Sara J. Venters, Sara Kochanny, Anran Li +31 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

Rita Nanda

Indexed papers

Top data-sharing exemplar

Papers